Ann: Placement, page-14

compared to Biotron...it’s an outstanding success and while I see risks to the Balance Sheet if US sales don’t stack up to targets, management are now actively and transparently engaging with their shareholders

They seem to have a very interesting pipeline and whilst it may not reflect positively on the Balance Sheet through trials, there may be an up ramp in market interest and optimistic speculation

I have particular interest around the scar treatment development as there are many people who are affected by keloids after surgery and even acne

If clinical trials show significant improvement in wound healing and dramatic improvement in established and keloid scars, then expect this to ROCKET to a billion dollar company (only negative is that it’s an ASX company)

The current and future demand for inflammatory disease treatments is going to increase exponentially